LAWS(DLH)-2021-7-203

ASTRAZENECA AB Vs. INTAS PHARMACEUTICALS LTD.

Decided On July 20, 2021
Astrazeneca Ab Appellant
V/S
INTAS PHARMACEUTICALS LTD. Respondents

JUDGEMENT

(1.) All these nine appeals, under Section 13(1A) of the Commercial Courts Act, 2015 read with Order XLIII Rule 1(r) of the Code of Civil Procedure, 1908 (CPC), impugn the orders/judgments of denial of interim relief, in suits instituted by the appellants/plaintiffs i.e. (i) AstraZeneca AB, Sweden and (ii) AstraZeneca Pharma India Ltd. against the respondent(s)/defendant(s) in each of the appeals, for permanent injunction restraining infringement of patent and for ancillary reliefs.

(2.) FAO(OS)(COMM) 139/2020 and FAO(OS)(COMM) 140/2020 impugn the common order/judgment dated 2nd November, 2020 in CS(COMM) No.410/2020 and in CS(COMM) No.411/2020 filed by the appellants/plaintiffs against Intas Pharmaceuticals Ltd. and Alkem Laboratories Ltd. respectively.

(3.) FAO(OS)(COMM) 155/2020, FAO(OS)(COMM) 156/2020, FAO(OS)(COMM) 157/2020, FAO(OS)(COMM) 158/2020, FAO(OS)(COMM) 159/2020, FAO(OS)(COMM) 160/2020 and FAO(OS)(COMM) 161/2020 impugn the common order/judgment dated 18th November, 2020 in suits filed by the same appellants/plaintiffs, being (i) CS(COMM) No.323/2020 against Torrent Pharmaceuticals Ltd.; (ii) CS(COMM) No.346/2020 against Micro Labs Limited; (iii) CS(COM) No.414/2020 against Zydus Healthcare Ltd. and Zydus Medica; (iv) CS(COMM) No.418/202 against Eris Lifesciences Ltd.; (v) CS(COMM) No.419/2020 against USV Pvt. Ltd.; (vi) CS(COMM) No.426/2020 against MSN Laboratories Pvt. Ltd.; and, (vii) CS(COMM) No.154/2020 against Ajanta Pharma Ltd.